Results 111 to 120 of about 23,173 (138)

Continuous infusion versus intermittent dosing of ceftazidime/avibactam in critically ill patients with <i>Klebsiella pneumoniae</i> OXA-48 or <i>Pseudomonas aeruginosa</i> infections: a single-center randomized open-label trial (ZAVICONT). Rationale and design. [PDF]

Front Pharmacol
Momčilović M, Šitum I, Erceg A, Siroglavić M, Lovrić M, Nižić Nodilo L, Hafner A, Lovrić J, Turčić P, Fabijanović D, Marinić A, Nedeljković V, Pašalić M, Perčin L, Šipuš D, Miličić D, Lovrić D.   +16 more
europepmc   +1 more source

Emergence of OXA-48-producing Klebsiella pneumoniae in Lithuania, 2023: a multi-cluster, multi-hospital outbreak. [PDF]

Euro Surveill
Greičius P, Linkevicius M, Razmuk J, Sinotova J, Alm E, Svartström O, Bortolaia V, Kudirkienė E, Roer L, Hendriksen RS, Tamoliūnaitė G, Palm D, Monnet DL, Kohlenberg A, Griškevičius A.   +14 more
europepmc   +1 more source

Evaluation of the KPC/IMP/NDM/VIM/OXA-48 Combo Test Kit and Carbapenem-Resistant K.N.I.V.O. Detection K-Set in detecting KPC variants. [PDF]

J Clin Microbiol
Valério de Lima A, Lima KdO, Cappellano P, Cifuentes S, Lincopan N, Sampaio SCF, Sampaio JLM.   +6 more
europepmc   +1 more source

Ceftazidime-Avibactam Versus Polymyxin-Based Combination Therapies: A Study on 30-Day Mortality in Carbapenem-Resistant Enterobacterales Bloodstream Infections in an OXA-48-Endemic Region. [PDF]

Antibiotics (Basel)
Dumlu R, Şahin M, Derin O, Gül Ö, Başgönül S, Zengin R, Arabacı Ç, Şimşek F, Gençer S, Kocagöz AS, Mert A.   +10 more
europepmc   +1 more source

Role of amino acid 159 in carbapenem and temocillin hydrolysis of OXA-933, a novel OXA-48 variant. [PDF]

Antimicrob Agents Chemother
Rima M, Oueslati S, Cotelon G, Creton E, Bonnin RA, Dortet L, Iorga BI, Naas T.   +7 more
europepmc   +1 more source

Electrostatic interactions define nacubactam potency against OXA-48-like β-lactamases

Hoff JF, Goudar KE, Beer M, Hinchliffe P, Shaw JM, Tooke CL, Takebayashi Y, Mulholland AJ, Schofield CJ, Spencer J.   +9 more
europepmc   +1 more source

Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying <i>bla</i>_OXA-48. [PDF]

Microbiol Spectr
Mojica MF, Zeiser ET, Becka SA, Six DA, Moeck G, Bonomo RA, Papp-Wallace KM.   +6 more
europepmc   +1 more source

Combination Therapy for OXA-48 Carbapenemase-Producing Klebsiella Pneumoniae Bloodstream Infections in Premature Infant: A Case Report and Literature Review. [PDF]

Infect Drug Resist
Chen Y, Fang C, Luo J, Pan X, Gao Z, Tang S, Li M.   +6 more
europepmc   +1 more source

In vitro activity of ceftazidime-avibactam and comparators against OXA-48-like Enterobacterales collected between 2016 and 2020. [PDF]

Microbiol Spectr
Stone G, Wise M, Utt E.
europepmc   +1 more source